We developed a diagnostic test based on the reverse dot-blot principle, in which five mitochondrial point mutations responsible for Leber hereditary optic neuropathy (LHON) were screened simultaneously. A series of wild-type and mutant oligonucleotides representing each mutation were covalently bound to a single nylon membrane strip. The target sites were amplified in a multiplex PCR and the products were hybridized to the membrane. Detection is based on chemiluminescence. To test the developed assay, 47 patients suspected of having LHON were screened. In 11 cases (23%) the diagnosis of LHON could be confirmed (3460, 1; 9804, 1; 11778, 5; 14484, 3; 15257, 1). The results suggest that the clinical identification of the mitochondrial defect is not trivial and the availability of a rapid screening method simplifies the molecular analysis of these cases.
Mitochondrial diseases have gained importance in clinical practice, since, at least for some of them, a defect of the mitochondrial genome can be identified. Partial deletions of the mitochondrial DNA (mtDNA) were first described in patients with mitochondrial disorders in 1988 (chronic progressive external ophthalmoplegia and Kearns-Sayre syndrome) [1] and have later also been identified in neonates with Pearson bone marrow-pancreas syndrome [2] , in Wolfram syndrome [3] , combinations of diabetes and deafness [4] , and others. 1 In 1989, the first point mutation in the mtDNA was identified in patients with Leber hereditary optic neuropathy (LHON) [5] . Soon after this, point mutations in the mitochondrial tRNA genes were found in patients with complex disorders such as myoclonic epilepsy with ragged red fibers and mitochondrial encephalomyopathy with lactic acidosis and strokelike episodes [6, 7] . Since then, the number of possibly pathogenic mtDNA mutations associated with disease has steadily increased [8] .
The mitochondrial genome has some unique genetic features. First, a human cell contains on average a few hundreds of mitochondria and a thousand copies of mtDNA. In most pathological cases both normal and mutant mtDNA occur in the same cell, a phenomenon called heteroplasmy. Second, because the mtDNA codes for proteins with a role in oxidative phosphorylation, organs that rely more readily on their energy supply will be more sensitive to mtDNA defects. Finally, mtDNA is transmitted through the cytoplasm of the egg, and the inheritance of the mutations is strictly maternal. The identification of a mutation thus has implications for all maternally related members of a family.
LHON (OMIM 535000, [9] ) is the most frequent cause of optic atrophy, and a good diagnostic test would supplement the clinical investigations. Currently, the assay of choice is one in which one can screen for several point mutations simultaneously, heteroplasmy can be detected, several samples can be processed in parallel, and is technically easy to handle.
Until now, LHON mutation detection has mainly been based on the gain or loss of restriction sites [5] , or on allele-specific amplification [10] . These methods are accurate and deal with the problem of heteroplasmy but are time consuming. Single-stranded conformation polymorphism analysis has also been used for screening of the mitochondrial genome [11] . These methods have the potential to identify any mutation in a particular region of the mtDNA, although with only 60 -80% efficiency [11] . However, given the number of polymorphisms in the mitochondrial genome, false positives may occur often
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and direct sequencing becomes a requisite. Solid-phase microsequencing has thus far been the most sensitive direct assay [12] . Although this method is very sensitive and amenable to automation and microchip technology [13] , it is relatively time consuming in its present format.
We chose to develop a reverse dot blot (RDB) as a practical solution to mtDNA point mutation screening. The method, based on the discriminative hybridization of single-base mismatches, is simple and fast, while the range of mutations can easily be expanded. The format is suitable for commercialization.
The five most frequent, primary mutations responsible for LHON (3460, 9804, 11778, 14484, 15257 [9] ) are included and the LHON assay was tested on 47 consecutive patients; for 11 patients the clinical diagnosis was confirmed.
Materials and Methods multiplex pcr
Multiplex PCR amplification with five pairs of primers (Table 1) was done in 50 L of 1ϫ buffer (Gene Amp, 10ϫ PCR-Buffer II; Perkin-Elmer, Norwalk, CT and Roche Molecular Systems, Branchburg, NJ) containing 2 mmol/L MgCl 2 , 0.2 mmol/L dNTPs, and 2U of AmpliTaq polymerase (Perkin-Elmer). Primers were used at the concentrations described in Table 1 . One primer of each pair was biotinylated. The oligonucleotides were purchased from Pharmacia Biotech (Roosendaal, The Netherlands) or Eurogentec (Seraing, Belgium). The reactions were performed on 300 ng of genomic DNA in a GeneAmp 2400 (Perkin-Elmer) with 30 cycles of denaturation for 30 s at 94°C, annealing for 30 s at 57°C, extension for 30 s at 68°C, and a final extension of 10 min at 68°C. After amplification, 5 L of the PCR mix was analyzed on a 2% agarose gel.
preparation of the membrane
Preparation of the Biodyne C membrane (Pall BioSupport, Portmouth, NJ) was essentially done as described by Zhang et al. [14] . The membranes were rinsed in 0.1 mol/L HCl, dried briefly, and activated in 200 g/L 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDAC) for 15 min. Then the filters were rinsed twice in H 2 O and dried at room temperature for 10 min. Synthetic oligonucleotides with a 5Ј amino linker (RDB oligonucleotides) were covalently bound to the activated carboxyl groups of the membrane. These oligonucleotides were purchased from Pharmacia Biotech (TFA-amino linker) or Eurogentec (C12 amino modifier). The oligonucleotides were diluted in 0.5 mol/L NaHCO 3 , pH 8.4 (see Table 2 ), and 2 L of this dilution was spotted on the membrane. After 10 min of incubation, the remaining active groups were quenched with 0.1 mol/L NaOH for 10 min. Finally, the membranes were rinsed twice in H 2 O and air dried for immediate use or for storage.
hybridization and detection
The membranes were prehybridized in 5ϫ saline-sodium phosphate-EDTA (SSPE) buffer (20ϫ SSPE is 3 mol/L NaCl, 200 mmol/L NaH 2 PO 4 , and 20 mmol/L EDTA at pH 7.4) and 5 g/L sodium dodecyl sulfate (SDS) at 50°C for 30 min. Forty microliters of multiplex PCR product was denatured with 1.6 L of 5 mol/L NaOH for 5 min at 65°C and diluted in 2 mL of hybridization solution (5ϫ SSPE, 5 g/L SDS), after which the strips were hybridized for 30 min at 50°C. The membranes were washed in 3 mol/L tetramethylammonium chloride (TMAC) at 50°C for 15 min [14] . Since detection was performed with a chemiluminescent reaction kit (Chemiluminescent kit; Tropix, Bedford, MA), the PCR primer of the strand complementary to the RDB oligonucleotide was biotinylated. The reaction was essentially done according to the manufacturers' protocol. The filters were first blocked with I-light blocking reagent and then incubated with streptavidin-alkaline phosphatase conjugate. After the washing steps, the membranes were incubated with the AMPPD [3-(2'-spiroadamantane)-4-methoxy-4-(3'-phosphoryloxylphenyl-1,2-dioxetane] substrate, activated at 
test samples
For optimization, short wild-type (WT) and mutant-type (MT) fragments were generated for each mutation by PCR with the RDB oligonucleotide that detects the mutation of interest as an amplification primer together with the biotinylated PCR primer normally used for amplification of the fragment (Table 1 ) [15, 16] . Total DNA samples were obtained from lymphocytes by using a salt extraction method. Samples from patients with the 3460, 11778, 14484, and 15257 mutations were a gift from J.P. Bonnefont, Hô pital Necker, Paris. In the course of the experiments, patients with these mutations and the 9804 mutation were identified (see Results).
At the time of analysis, the laboratory had also collected 47 samples from patients with optic atrophy, with either a definitive or a tentative clinical diagnosis of LHON. These samples had been collected after informed consent.
Results

test design
Selection of mutations. Up to now, 17 mtDNA mutations have been observed in association with LHON [9] . These mutations are all substitutions in the protein coding regions of mtDNA. They vary in their propensity for causing the disease ("primary" and "secondary" mutations) [17] and are homoplasmic or nearly so (40 -90% in affected persons). For this assay, five mutations were selected (3460, 9804, 11778, 14484, 15257) to cover ϳ90% of west European LHON patients. The 11778 G-to-A transition accounts for ϳ50% of European cases. The 3460 G-to-A mutation is responsible for up to 35% of European LHON. The 14484 A-to-G mutation accounts for up to 20% of LHON in some studies, and is often associated with secondary mutations. There is some controversy in the literature about the exact nature of the 15257 G-to-A mutation: Although it is considered a primary mutation, it is the mildest mutation and it was observed together with other primary or secondary mutations in all but one case [18 -20] . The 9804 G-to-A mutation is probably also a primary cause of LHON, although this must be further substantiated [21] . The most severe primary mutation at 14459 is associated with LHON and neurogenic symptoms. It was not yet included in the test because it has only been described in one family [22] . Secondary mutations were not included in the test.
RDB. The RDB principle [15, 23] was chosen as a useful method for detection of mtDNA point mutations. The assay had to fulfill three criteria: (a) a stringent hybridization to discriminate between oligonucleotides differing in only one base pair, (b) the same hybridization conditions for all WT/MT oligonucleotide pairs, and (c) a high sensitivity to detect a low percentage of heteroplasmy.
Instead of the classical poly-T tailing [15, 23] , covalent attachment of the oligonucleotides to the membrane via an amino linker was preferred. As reported by Zhang et al. [14] , covalent linkage provides an increased sensitivity of the assay compared with the T-tail-based attachment. The use of a spacer between the amino group and the oligonucleotide had no influence on the binding efficiency to the membranes (data not shown).
To simplify the optimization of the hybridizations, TMAC was chosen for the posthybridization washes. This quaternary ammonium salt essentially eliminates disparities in the melting temperatures (T m s) of the oligonucleotides [24] . Indeed, a better discrimination was obtained after washing with 3 mol/L TMAC compared with 0.5ϫ saline-sodium citrate (SSC) (20ϫ SSC is 3 mol/L NaCl, 0.3 mol/L sodium citrate at pH 7.0) and 1 g/L SDS (data not shown).
optimization of rdb
On the basis of the idea that 3 mol/L TMAC in the hybridization reactions would eliminate the dependence of the T m on G-C content, all RDB oligonucleotides were initially 18 bp long. At 50°C, a specific hybridization was achieved with the WT and MT primers for 3460 and 9804. By varying the length and shifting the position of the oligonucleotides, more mutations were detected under uniform hybridization conditions. In our hands, TMAC was thus not as good a reagent as proposed. Also, the short synthetic mutant fragments were an easy tool for optimization of the RDB, although in certain cases the specific signal that was obtained with the short fragments was not obtained with the full-size fragments ( Fig. 1 and  data not shown) .
The concentration of the oligonucleotides is a second parameter that influences the discrimination between MT and WT. This has been tested in the same set of experiments. The oligonucleotides were applied to the membrane in dilution series ranging from 10 to 0.25 pmol (Fig.  1) . WT oligonucleotide concentrations, which gave a strong signal when hybridized with WT probe and no signal with the MT probe, were chosen and vice versa. The sequence and concentration of the oligonucleotides used in the final assay are given in Table 2 . All target regions, i.e., five fragments of 210 to 833 bp, encompassing the different mutations, were amplified in one multiplex PCR (Fig. 2) . The fragment lengths and primer sets are given in Table 1 .
screening for lhon
The LHON strip was tested on 47 samples. Several outcomes were assembled in Fig. 3 . For 11 patients, the diagnosis was confirmed: Five showed the mutation at 11778 (an example is given in lane 4), three the mutation at 14484 (lane 5), one had the 3460 mutation (lane 2), one the rare 9804 mutation (lane 3), and one was positive for 15257 (lane 6). All these mutations were virtually homoplasmic. Fig. 3 shows an additional feature of the RDB assay: A polymorphism in the region covered by the RDB oligonucleotide results in the absence of a signal for both the WT and MT oligonucleotides (lane 7). Sequencing showed the presence of a polymorphism at position 3459 in this patient.
Discussion
An efficient and sensitive method for screening is an important tool to address genetic heterogeneity andspecifically for mtDNA mutations-heteroplasmy, in the molecular genetics laboratory. In our hands, the RDB was a fast, sensitive, and easy system to screen for multiple mutations in a single assay. The RDB was already successfully applied in our laboratory for screening for cystic fibrosis transmembrane regulator (CFTR) mutations [15] and for HLA class II typing [25] . Besides, the RDB assay may be readily extended to detect additional mutations at minimal increase in cost and time per test. The INNO-LIPA format (Innogenetics, Zwijndrecht, Belgium) of the RDB can easily accommodate 14 mutations (up to 26 oligonucleotides on a single nylon strip). The turnaround time of the final assay was very good and would even be reduced by automation of the preparation of the membrane and the washing and detection procedures. Another advantage of this RDB assay is that one patient is screened on one strip. This ensures against sample confusion at any step. WT and MT RDB oligonucleotides were applied to the membrane in a dilution series ranging from 10 to 0.5 pmol. The strips were hybridized with the synthetic short WT fragment (WT short) and the short MT fragment (MT short). The short fragments were generated by PCR with primer 9804A and the respective RDB oligonucleotides. The results were compared with the hybridizations obtained with the full-size WT PCR fragment (WT long), as used in the final assay, and the full-size MT PCR fragment (MT long) obtained after amplification of the 9804 patient's DNA (see Results). Good results were obtained with the covalent attachment of the amino-linked oligonucleotides to the negatively charged membranes. Compared with T-tailed oligonucleotides they are easier to use, the covalent binding is more reproducible, and a higher sensitivity can be achieved [14] . TMAC was used in the washing buffer. However, the exact conditions for a dependence of the T m purely on length were not achieved. Less than half (4 of 10) of the original oligonucleotides of 18 bp were retained in the final assay. For the remaining RDB oligonucleotides, both length and position still had to be empirically determined.
The detection criteria for LHON mutations are less stringent than for mtDNA mutations associated with mitochondrial encephalo(myo)pathies, since LHON mutations are almost always homoplasmic in affected individuals. The RDB assay easily detects mutations in twoallelic systems [15, 23] . Moreover, control experiments have shown that low percentages of heteroplasmy (Ͻ1%) are readily detected (unpublished data).
Obermaier-Kusser et al. [18] have described 12 different combinations of mutations in 21 of 29 LHON patients or families (72%). With this assay, we would have detected 81% of their confirmed LHON patients, missing those patients that harbor only secondary mutations. It would therefore be interesting to add the 4216 and 13708 mutations to the assay. On the other hand, the low number of positives in the present screening is due to the fact that the samples were tested as they presented in the diagnostic laboratory, without stringent clinical review of the symptomatology.
The sample included five unrelated cases of 11778. These had previously been identified by SfaNI digestion. The assay detected four different mutations in six other, unrelated patients. Thus, the 11778 mutation is responsible for almost 50% of LHON cases, as was previously noted. It is interesting to note that a patient with the mutation at 9804 was identified. Only three patients with this mutation were described thus far [21] .
In conclusion, this RDB assay covers the most frequently observed mutations and greatly facilitates the molecular diagnosis of LHON.
